Kinetics of Biomarkers in Acute Pyelonephritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00805181 |
Recruitment Status
:
Completed
First Posted
: December 9, 2008
Last Update Posted
: October 7, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Pyelonephritis |
Study Type : | Observational |
Estimated Enrollment : | 30 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | April 2010 |
Actual Study Completion Date : | April 2010 |
Group/Cohort |
---|
Acute uncomplicated pyelonephritis |
- Blood and urine biomarkers (procalcitonin, C-reactive protein, SIGNATURE(TM) test, pyuria [ Time Frame: Daily till day 15. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- > 18 years
- Flank/loin pain or tenderness, or both and fever > 38°C during the last 48 hours and pyuria
Exclusion Criteria:
- Pregnancy
- Presence of indwelling catheters
- Known polycystic kidney disease or any malformation of the urinary tract, or single kidney; renal transplant recipients; acute or chronic renal failure requiring dialysis
- Recent discharge from hospital (during the last 10 days); ongoing antibiotic treatment
- Known severe immunosuppression: Receiver of solid-organ or hematopoietic stem cells transplants; neutropenia ( < 1 G neutrophils / L); chronic (more than 14 days) use of systemic glucocorticoids (>10 mg/d of prednisone); active use of immunosuppressive therapy for the treatment of auto-immune or inflammatory disease; HIV infection with < 350 CD4+ cells / ml or unknown CD4+ status
- Pyelonephritis initially identified as complicated: obstruction of urinary tract, urinary stone; history of renal infection in the last 15 days
- Patient with severe sepsis or septic shock

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00805181
Switzerland | |
Geneva University Hospitals | |
Geneva, Switzerland, 1211 |
Principal Investigator: | Olivier T Rutschmann, MD, MPH | University Hospital, Geneva |
Responsible Party: | Medical Director, University Hospital, Geneva |
ClinicalTrials.gov Identifier: | NCT00805181 History of Changes |
Other Study ID Numbers: |
CER08-170 PRD-08-I-4 |
First Posted: | December 9, 2008 Key Record Dates |
Last Update Posted: | October 7, 2010 |
Last Verified: | June 2010 |
Additional relevant MeSH terms:
Pyelonephritis Nephritis, Interstitial Nephritis |
Kidney Diseases Urologic Diseases Pyelitis |